The U.S. Food and Drug Administration (FDA) has accepted Xspray Pharma's resubmitted New Drug Application (NDA) for Dasynoc® for review under the 505(b)(2) procedure. The FDA has set a PDUFA date of ...
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has announced the publication 1 in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial ...
Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology ...
Reported positive initial Phase 1b data for ELVN-001 in CML Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 ...
Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money.RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc.
Reflecting on the strength of the community and engagement, Dr. Chaubey said, “Symposium 2026 is a living example of turning possibility into reality – a community united by the desire to be among the ...
Xspray Pharma AB (publ) has re-submitted its application for market approval for Dasynoc® to the U.S. Food and Drug Administration (FDA). Dasynoc® is the company's lead product candidate - an amorphou ...
cml-mcp brings the power of AI assistants to your network lab! This tool allows you to interact with Cisco Modeling Labs (CML) using natural language through AI applications like Claude Desktop, ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) ('Ascentage Pharma” or the 'Company”), a global, commercial ...
Accelerated-phase CML is characterized by faster progression than chronic phase, with variable symptom burden including fatigue, weight loss, night sweats, bruising, and splenic enlargement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results